NCT06072131 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06072131
Title	To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL (CRESCENDO)
Acronym	CRESCENDO
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Acrotech Biopharma Inc.
Indications	anaplastic large cell lymphoma hepatosplenic T-cell lymphoma angioimmunoblastic T-cell lymphoma peripheral T-cell lymphoma nasal type extranodal NK/T-cell lymphoma
Therapies	Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Cyclophosphamide + Pralatrexate + Prednisone + Vincristine Sulfate Belinostat + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| ITA \| HUN \| ESP \| DEU \| CAN

Additional content available in CKB BOOST